Development of an Epigenetic Biomarker discovery platform for liquid biopsis
| Reference number | |
| Coordinator | Epigenica AB |
| Funding from Vinnova | SEK 1 907 895 |
| Project duration | November 2024 - April 2026 |
| Status | Completed |
| Venture | Acceleration of deep tech companies |
| Call | Acceleration of deep tech companies 2024 |
Important results from the project
The project achieved its original objectives. Epigenica validated customer needs, pricing and segment focus, further developed an epigenetic biomarker platform for liquid biopsies, strengthened the analysis workflow and completed KOL and beta activities. The work also improved processes for GDPR, data evaluation and commercial market introduction.
Expected long term effects
In the long term, the results can support broader use of liquid biopsies for epigenetic biomarker analysis in translational research. The platform may enable more standardized analyses, shorter timelines, better comparability between studies and new collaborations across research, healthcare, drug development and industry.
Approach and implementation
The project was implemented through work packages for market validation, antibody panel development, analysis tools, KOL and beta activities, and final kit specifications. The structure worked well. Customer and KOL feedback guided priorities, and key learnings led to adjustments in data flow, agreements, GDPR and future product development.